The Column Group/NGM $6M Securities Settlement
If you owned NGM Biopharmaceuticals Inc. (Nasdaq: NGM) common stock on April 5, 2024 and either received $1.55 per share in the take-private transaction or dissented, you may automatically receive a cash payment from a $6 million settlement. No claim form is required—the administrator will pay you directly. Review the key details below and stay on top of important dates.
Download Claim Form (PDF)At a Glance
- Settlement Fund: $6,000,000
- Estimated Payout: Pro rata based on eligible shares
- Claim Form: Not required
- Fairness Hearing: October 21, 2025
- Settlement Website: ngmstockholderlitigationsettlement.com
- Settlement Administrator: A.B. Data – 1-800-431-9392
- Court Case: Bryant v. The Column Group LP et al., No. 2024-1314-MTZ
Who Is Eligible?
You are part of the class if all of the following apply:
- Held NGM Biopharmaceuticals common stock as a record holder or beneficial owner on April 5, 2024.
- Either received $1.55 per share in cash when the take-private deal closed or formally dissented from the transaction.
Heirs, successors, transferees and assigns of eligible shareholders are included. “Rollover stockholders” who exchanged their shares for equity in the new private company are excluded.
How Much Will You Receive?
The $6 million fund will be reduced by taxes, notice and administration costs (capped at $250,000), attorneys’ fees and expenses (up to 20 %), and any service award (up to $5,000). The remainder—known as the Net Settlement Fund—is divided pro rata among all eligible shares.
Formula: Net Settlement Fund ÷ Total Eligible Shares (≈ 43.8 million) = Per-share payment.
Payment Delivery
- Shares in brokerage account: Cash is credited to the same account.
- Registered shareholders: Check or electronic transfer from the administrator.
No further action is needed unless the administrator contacts you to verify payment details.
Why Is There a Settlement?
The lawsuit alleged that The Column Group LP, as a controlling shareholder, and certain directors/officers breached fiduciary duties in connection with the April 2024 acquisition of NGM Biopharmaceuticals by:
- Setting an unfair cash-out price of $1.55 per share,
- Failing to provide adequate disclosures, and
- Engaging in conflicts of interest.
Defendants denied wrongdoing but agreed to the $6 million settlement to avoid ongoing litigation costs and risks.
Key Dates
- Final Approval / Fairness Hearing: October 21, 2025
- Payout Timeline: Payments are issued after the court grants final approval and any appeals are resolved. No specific payment date is set yet.
Frequently Asked Questions
Do I have to submit a claim for The Column Group/NGM $6M Securities Settlement?
No. Eligible shareholders will be paid automatically; the administrator already has the necessary transaction records.
How will my pro rata payment be calculated?
The Net Settlement Fund (after deductions) is divided by the total number of eligible shares (~43.8 million). Multiply that per-share amount by the number of eligible shares you owned.
When will I get paid from the The Column Group/NGM settlement?
Payments will be distributed after the court’s final approval on or after October 21, 2025 and after any appeals. Processing often takes several months; monitor the settlement website for updates.
Who can I contact with questions about the settlement?
A.B. Data, the settlement administrator:
NGM Stockholder Litigation Settlement
P.O. Box 170500, Milwaukee, WI 53217
1-800-431-9392
info@ngmstockholderlitigationsettlement.com